<DOC>
	<DOCNO>NCT02395471</DOCNO>
	<brief_summary>This study ass Minimally Invasive Esophageal Cytology Collection System Patients Barrett 's Esophagus GERD Symptoms .</brief_summary>
	<brief_title>Cytosponge Adequacy Study Evaluation II</brief_title>
	<detailed_description>This cross-sectional study subject Barrett 's esophagus ( BE ) assess utility Cytosponge device non-endoscopic method collect surface cell esophagus . This study enroll 2 group subject : 1 ) Subjects present routine endoscopic BE surveillance examination ( n=120 ) , 2 ) Subjects gastroesophageal reflux disease ( GERD ) symptoms undergoing upper endoscopy screen BE ( n=55 ) . After informed consent , day endoscopic procedure , subject undergo administration Cytosponge device complete questionnaire . The subject undergo routine upper endoscopy , assessment BE ( applicable ) , biopsy per accept surveillance screen recommendation . The Cytosponge place fixative ship accredited pathology laboratory embed paraffin hematoxylin eosin ( H &amp; E ) stain assess adequacy specimen . Further evaluation specimen may perform use trefoil factor 3 ( TFF3 ) . If Cytosponge tissue specimen inadequate , subject recall repeat sponge procedure ( endoscopy ) 30 day later . Routine care tissue biopsy undergo standard processing H &amp; E stain home institution , assessment expert gastrointestinal pathologist . Subjects contact via phone 7 day ( +/- 2 day ) Cytosponge administration complete additional questionnaire assess adverse event .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>1 . Male female patient , age 18 . 2 . Able read , comprehend , complete consent form . 3 . Clinically fit endoscopy . 4 . Previous confirm diagnosis BE intestinal metaplasia . Prague classification least least one circumferential centimeter BE total BE segment length least 3 centimeter ( BE arm ) last 3 year 5 . Selfreported heartburn regurgitation least monthly basis least 6 month ( GERD arm ) . 1 . Individuals diagnosis oropharynx , esophageal gastroesophageal tumor , ongoing symptom dysphagia . 2 . Any history esophageal varix , active stricture . 3 . Current use blood thinner coumadin , warfarin , clopidogrel , heparin and/or low molecular weight heparin ( require discontinuation medication 5 day prior 6 day EGD ) . 4 . Known bleed disorder . 5 . Individuals myocardial infarction cardiac event &lt; 6 month prior enrollment . 6 . Individuals cerebrovascular event &lt; 6 month prior enrollment swallow affected . 7 . Prior ablative resection therapy esophagus include radiofrequency ablation ( RFA ) , photodynamic therapy ( PDT ) , spray cryotherapy , endoscopic mucosal resection , ablation therapy . 8 . Any history esophageal surgery , except uncomplicated fundoplication . 9 . Do need upper endoscopy part patient management . 10 . Planned ablation therapy ( include endoscopic mucosal resection submucosal dissection ) within 3 day Cytosponge administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>